(LEXXW) – Accesswire
-
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
-
Lexaria Awarded New Patents
-
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
-
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
-
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
-
7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study
-
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
-
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
-
Lexaria Releases Annual Letter from the CEO
-
Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program
-
Lexaria's Investigational New Drug Application Filing Update
-
Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study
-
Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
-
Lexaria Granted Two New Patents in Canada
-
Lexaria Announces Pricing of $1.6 Million Registered Direct Offering
-
Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD
-
Lexaria Provides Update on Investigational New Drug Application Progress
-
Lexaria's DehydraTECH-Nicotine Faster than ZYN and on!
-
Lexaria’s Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD
-
Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study
-
Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products
-
Lexaria's Groundbreaking Research into DehydraTECH-CBD Published in International Journal of Molecular Science
-
Lexaria Receives New Patents
-
Lexaria’s DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study
-
Lexaria Appoints New Chief Financial Officer
-
Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers
-
Lexaria's Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery
-
Lexaria Bioscience Announces Closing of $2.0 Million Public Offering
-
cGMP Manufacturing Complete for Lexaria's Upcoming U.S. Phase 1b Hypertension Clinical Trial
-
Lexaria Announces 2023 Annual Meeting Results
-
Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering
-
Lexaria’s Human Clinical Nicotine Study Completes Dosing as Planned
-
Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study
-
Lexaria is Receiving Four New Patents
-
Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride and Cholesterol Levels
-
Lexaria Discovers Potential Novel Mechanism From Hypertension Study HYPER-H21-4
-
Former President of GW Pharmaceuticals USA Joins Lexaria Bioscience as Strategic Advisor
-
Lexaria Releases Annual Letter from the CEO
-
Lexaria Releases Annual Letter from the CEO
-
Lexaria Receives First Granted Patent in Canada
-
Lexaria's DehydraTECH-CBD Achieves Superior Human Blood Absorption Levels
-
Lexaria’s Human Oral Nicotine Study Begins Dosing
-
Lexaria’s DehydraTECH-CBD(TM) Enhances Performance Compared to Epidiolex(R) in Seizure Study Program
-
Lexaria Examining Potential Therapeutic Use of DehydraTECH-CBD in Dementia
-
Lexaria Starts Study Evaluating the Effect of DehydraTECH-CBD on Diabetes
-
Lexaria Receives Independent Review Board Approval for its Upcoming Human Oral Nicotine Study
-
Lexaria's Human Clinical Hypertension Study a Success
-
Lexaria Welcomes Dr. Catherine Turkel to its Board of Directors
-
Lexaria Receives New Patent in Mexico
-
Lexaria Discusses Valuation Metrics for Biotech Industry
Back to LEXXW Stock Lookup
